Patents by Inventor Suk Peng Chew

Suk Peng Chew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for classifying cancer patients into appropriate hepatocellular carcinoma treatment groups and compounds for treating the patient
    Patent number: 12276664
    Abstract: A method for the prognosis of response to treatment for a patient suffering from cancer, the method comprising: measuring the expression of at least one immune marker in a leukocyte sample taken from the patient with cancer; classifying the patient sample into (i) sustainable responders (SR) to selective internal radiation therapy (SIRT) or (ii) transient/non-responders (TR/NR) to (SIRT) based on expression of the at least one immune marker in relation to a predetermined value and treating sustainable responders (SR) to SIRT or SIRT or a composition comprising SIRT and an immunotherapy. In a preferred embodiment, the method is for the prognosis of response to treatment of a Hepatocellular carcinoma (HCC) patient comprising detecting the co-expression of PD-1 or Tim-3 with CCR5; or expression of PD-1, Tim-3, CXCR6, or combinations thereof in a leukocyte sample taken from the patient.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: April 15, 2025
    Assignee: SINGAPORE HEALTH SERVICES PTE. LTD.
    Inventors: Suk Peng Chew, Salvatore Albani, Kah-Hoe Pierce Chow, Lu Pan
  • SYSTEM AND METHOD FOR CLASSIFYING CANCER PATIENTS INTO APPROPRIATE CANCER TREATMENT GROUPS AND COMPOUNDS FOR TREATING THE PATIENT
    Publication number: 20210341483
    Abstract: A method for the prognosis of response to treatment for a patient suffering from cancer, the method comprising: measuring the expression of at least one immune marker in a leukocyte sample taken from the patient with cancer; classifying the patient sample into (i) sustainable responders (SR) to selective internal radiation therapy (SIRT) or (ii) transient/non-responders (TR/NR) to (SIRT) based on expression of the at least one immune marker in relation to a predetermined value and treating sustainable responders (SR) to SIRT or SIRT or a composition comprising SIRT and an immunotherapy. In a preferred embodiment, the method is for the prognosis of response to treatment of a Hepatocellular carcinoma (HCC) patient comprising detecting the co-expression of PD-1 or Tim-3 with CCR5; or expression of PD-1, Tim-3, CXCR6, or combinations thereof in a leukocyte sample taken from the patient.
    Type: Application
    Filed: November 29, 2018
    Publication date: November 4, 2021
    Applicant: SINGAPORE HEALTH SERVICES PTE. LTD.
    Inventors: Suk Peng CHEW, Salvatore ALBANI, Kah-Hoe Pierce CHOW, Lu PAN
  • GENE SIGNATURES FOR USE WITH HEPATOCELLULAR CARCINOMA
    Publication number: 20140017227
    Abstract: The present invention provides a method for predicting prognosis of hepatocellular carcinoma patients based on measurement of the relative level of expression of a combination of 15 immune genes of interest, or a subset thereof, in the tumors of such patients. Tumor material can come from surgical resection or biopsy. The relative gene expression information may be combined in an algorithm. The signature can be used by itself or in combination with other information such as stage information.
    Type: Application
    Filed: January 13, 2012
    Publication date: January 16, 2014
    Inventors: Suk Peng Chew, Alessandra Nardin, Jean-Pierre Abastado, JinMiao Chen, Henry Yang